Sponsor

Amarex Clinical Research

Clinical research sponsor

Published trials8
Recruiting shown2
Roles1
SourceClinicalTrials.gov

Clinical trials

8 shown
A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUsNCT07116174 · collaborator · 2025-08-15
RECRUITING
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in AdultsNCT03094429 · collaborator · 2017-03-29
RECRUITING
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy VolunteersNCT05844787 · collaborator · 2022-07-11
COMPLETED
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )NCT04426201 · collaborator · 2020-12-20
TERMINATED
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBCNCT03838367 · collaborator · 2019-04-22
TERMINATED
Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 InfectionNCT02175680 · collaborator · 2014-04-16
COMPLETED
Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With DiabetesNCT01421966 · collaborator · 2011-08-01
COMPLETED
An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 StudyNCT02759042 · collaborator
NO_LONGER_AVAILABLE

Sponsor roles

collaborator8

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.